Muñiz Lobato Sara, Tarrazo Tarrazo Carlos, González Fernández Elena, Morán Alcalá Marlén
Servicio Hematología y Hemoterapia, Hospital Universitario San Agustín, Avilés, Spain.
Servicio Medicina Interna, Hospital Universitario San Agustín, Avilés, Spain.
Future Cardiol. 2018 May;14(3s):17-24. doi: 10.2217/fca-2018-0022.
To analyze the clinical profile and outcomes of patients with nonvalvular atrial fibrillation treated with rivaroxaban in a regional hospital.
Retrospective study of patients with nonvalvular atrial fibrillation that started treatment with rivaroxaban between July 2013 and May 2017 in a regional hospital.
189 patients (age 76.0 ± 9.4 years; CHADS-VASc 4.1 ± 1.7; HAS-BLED 2.1 ± 0.9) were included. Rivaroxaban 20 mg was taken by 74.1% of patients. Among patients treated with rivaroxaban 20 and 15 mg, only 3.6 and 22.5%, respectively, received an inadequate dose. After 26.6 ± 11.6 months of treatment, annual discontinuation rate was 1%. Rates of stroke, major bleeding and intracranial hemorrhage were 0.45, 0.22 and 0.22 events/100 patient years, respectively.
In our practice of regional hospital, rates of discontinuation, thromboembolic and bleeding outcomes are low.
分析在一家地区医院接受利伐沙班治疗的非瓣膜性心房颤动患者的临床特征及治疗结果。
对2013年7月至2017年5月期间在一家地区医院开始接受利伐沙班治疗的非瓣膜性心房颤动患者进行回顾性研究。
共纳入189例患者（年龄76.0±9.4岁；CHADS-VASc评分4.1±1.7；HAS-BLED评分2.1±0.9）。74.1%的患者服用利伐沙班20mg。在接受利伐沙班20mg和15mg治疗的患者中，分别仅有3.6%和22.5%的患者服用剂量不足。经过26.6±11.6个月的治疗，年停药率为1%。卒中、大出血和颅内出血发生率分别为0.45、0.22和0.22事件/100患者年。
在我们地区医院的实际治疗中，停药率、血栓栓塞和出血发生率较低。
